Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)

Lung Diseases, Interstitial Clinical Trial

Official title:

Ambispective, Non-Interventional Study to Evaluate the Epidemiology of Interstitial Lung Diseases (ILDs) Associated to Rheumatic Diseases (Rheumatoid Arthritis, Connective Tissue Diseases, Spondylarthritis and Sarcoidosis) and the Progression Risk Factors in the Mexican Population

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05819385
• Other study ID #: 1199-0522
• Status: Not yet recruiting
• Start date: April 22, 2024
• Est. completion date: October 17, 2026

Study information

• Verified date: April 2024
• Source: Boehringer Ingelheim
• Contact: Boehringer Ingelheim
• Phone: 1-800-243-0127
• Email: clintriage.rdg[@]boehringer-ingelheim.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 312
• Est. completion date: October 17, 2026
• Est. primary completion date: October 17, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

For newly data collection:

• Male and female Patients.
• Patients over 18 years old.
• Patient who gives his/her signed informed consent to be able to use information about their condition.
• Patient who has the diagnosis of: rheumatoid arthritis, connective tissue disease (CTD) (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) Spondyloarthritis (SpA) or sarcoidosis, (accordingly with the updated clinical criteria for each pathology). Patient with any interstitial lung diseases (ILD) diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).

For existing data collection:

• Medical Records from patients with whom contact was permanently lost for any reason since 2012 till the study start date.
• Medical Records from male and female Patients.
• Medical Records from patients over 18 years old.
• Medical Records of patients that have at least: patient initials, date of birth,

gender, date of diagnosis, full diagnosis of:

• Patient who has the diagnosis of: rheumatoid arthritis, CTD (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; Systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) SpA or Sarcoidosis, (accordingly with the updated clinical criteria for each pathology).
• Patient with any ILD diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).

Exclusion Criteria:

• Patient with a biopsy definition of usual interstitial pneumonitis, related to any other non-CTD.
• Patient with post-chemotherapy or post-radiotherapy pneumonitis.
• Medical Records of patients without full diagnostic of ILD (clinically and by biopsy or high-resolution computed tomography).

Related Conditions & MeSH terms

• Connective Tissue Diseases
• Lung Diseases
• Lung Diseases, Interstitial

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Boehringer Ingelheim	TIC Social

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to first exacerbation: time in months elapsed until the first exacerbation from the diagnosis		up to 13 years
Primary	Number of exacerbation per year (frequency of exacerbation)		up to 13 years
Primary	Percent of pulmonary fibrosis: grade of parenchymal involvement evidenced by high-resolution computed tomography (HRCT)		up to 13 years
Primary	Change in 6-minute walk tests (6-MWT) over time		up to 13 years
Primary	King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score change over time		up to 13 years
Primary	Saint George Respiratory Questionnaire (SGRQ)-I score change over time		up to 13 years
Secondary	Possibility to have an exacerbation and/or progression in pulmonary fibrosis, sorted by rheumatic disease type (rheumatoid arthritis (RA), connective tissue disease (CTD), spondyloarthritis (SpA) and Sarcoidosis)		up to 13 years
Secondary	Frequency of use of diagnostic tools (laboratory, cabinet)		up to 13 years
Secondary	Progression of pulmonary fibrosis by treatment received identified by HRCT patterns, lung function, activity score and damage index		up to 13 years

External Links

•   Related Info